Stocklytics Platform
Asset logo for symbol ETNB
89bio
ETNB52
$9.42arrow_drop_down1.65%-$0.16
Asset logo for symbol ETNB
ETNB52

$9.42

arrow_drop_down1.65%
no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Fundamentals
RPS-
Gross Profit-
Total Debt-
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ETNB-
US Healthcare Sector-
US Market-
warning

ETNB / Market

ETNB lose to the US Market which returned 0.03% over the last twenty four hours.
warning

ETNB / Healthcare Sector

ETNB lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

89bio (ETNB) Statistics

89bio Inc (ETNB) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. The company's mission is to improve the lives of patients by addressing significant unmet medical needs through the development of novel therapies. ETNB stock is traded on the Nasdaq stock exchange under the ticker symbol ETNB.
When it comes to valuation metrics, 89bio Inc has a market capitalization of approximately $300 million. The company's enterprise value is around $280 million, while its price-to-earnings ratio is not yet available as the company is still in the early stages of its development. Additionally, the company does not pay dividends at this time.
add 89bio  to watchlist

Keep an eye on 89bio

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has 89bio (ETNB) stock's performance compared to its sector and the market over the past year?

Over the past year, 89bio (ETNB) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, 89bio has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights 89bio 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of 89bio (ETNB) stock?

The PE ratio for 89bio (ETNB) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of 89bio (ETNB) stock?

The Earnings Per Share (EPS) for 89bio (ETNB), calculated on a diluted basis, is -$3.51. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of 89bio (ETNB) stock?

The operating margin for 89bio (ETNB) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of 89bio (ETNB) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of 89bio (ETNB) is -$384.62M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does 89bio (ETNB) have?

The total debt for 89bio (ETNB) is currently not available. The net debt for 89bio (ETNB) is currently not available.

Take Your Investments to a Whole New Level